Comment on "Probability of achieving treatments goals with twice-weekly teriparatide followed by bisphosphonate in Japanese postmenopausal osteoporosis".

This commentary evaluates the study by Takada et al. on sequential teriparatide bisphosphonate therapy in postmenopausal osteoporosis. While lumbar spine bone mineral density (BMD) targets are frequently met, the clinical validity of total hip BMD thresholds, especially in Asian populations, remains uncertain. We emphasize the need for fracture-based endpoints and caution against over-reliance on surrogate BMD targets in pre-treated patients.